Pathological pulmonary vascular remodeling is induced by type V collagen in a model of scleroderma.


Journal

Pathology, research and practice
ISSN: 1618-0631
Titre abrégé: Pathol Res Pract
Pays: Germany
ID NLM: 7806109

Informations de publication

Date de publication:
Apr 2021
Historique:
received: 04 11 2020
revised: 10 02 2021
accepted: 12 02 2021
pubmed: 2 3 2021
medline: 10 11 2021
entrez: 1 3 2021
Statut: ppublish

Résumé

The pulmonary vascular remodeling in systemic sclerosis (SSc) is poorly understood and animal models are lacking. Type V collagen (COLV) is elevated in SSc and is implicated in the pathogenesis, and immunization with human COLV induces SSc-like skin and lung changes in rabbits and mice. Here we tested the hypothesis that COLV immunization will induce pathological and functional changes that phenocopy SSc-associated pulmonary vascular disease. Pulmonary vascular changes in rabbits immunized with human COLV were extensively characterized by a combination of histology, electron microscopy and immunohistochemistry. Physiologic changes induced by COLV in explanted pulmonary artery rings were evaluated. The pattern of histopathologic alterations and gene expression induced in immunized rabbits were compared to those in SSc patients. COLV immunization was accompanied by striking pulmonary vascular abnormalities, characterized by reduced capillary density, perivascular inflammation, endothelial cell injury and collagen accumulation, that closely phenocopy changes seen in SSc patients. Moreover, pulmonary arteries from immunized rabbits showed impaired ex vivo vascular relaxation. Expression of COL5A2 was significantly increased in the lungs from immunized rabbits (p = 0.02), as well as in patients with SSc (P = 0.02). COLV immunity in rabbits is associated with marked vascular remodeling in the lung that phenocopies early-stage human SSc-associated pulmonary vascular disease. COLV immunization therefore represents a novel approach to model SSc pulmonary vascular pathology. Moreover, our findings suggest that COLV might represent a novel pathogenic autoantigen in SSc and future studies with the present model should be developed for possible association with PAH.

Identifiants

pubmed: 33647866
pii: S0344-0338(21)00043-1
doi: 10.1016/j.prp.2021.153382
pii:
doi:

Substances chimiques

Collagen Type V 0

Types de publication

Comparative Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

153382

Subventions

Organisme : NIH HHS
ID : K26 OD010945
Pays : United States
Organisme : NCRR NIH HHS
ID : K26 RR026099
Pays : United States

Informations de copyright

Copyright © 2021 Elsevier GmbH. All rights reserved.

Auteurs

Roberta Goncalves Marangoni (RG)

Rheumatology Division, Faculdade de Medicina da Universidade de São Paulo, São Paulo, SP, Brazil; Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, USA; Division of Allergy, Immunology and Rheumatology, University of Rochester Medical Center, Rochester, NY, USA. Electronic address: Roberta_Goncalvesmarangoni@urmc.rochester.edu.

Benjamin D Korman (BD)

Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, USA; Division of Allergy, Immunology and Rheumatology, University of Rochester Medical Center, Rochester, NY, USA.

Edwin R Parra (ER)

Department of Translational Molecular Pathology, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA.

Ana Paula P Velosa (APP)

Rheumatology Division, Faculdade de Medicina da Universidade de São Paulo, São Paulo, SP, Brazil.

Hermes V Barbeiro (HV)

Clinical Laboratory in Emergency Medicine, Faculdade de Medicina da Universidade de São Paulo, São Paulo, SP, Brazil.

Vanessa Martins (V)

Department of Translational Molecular Pathology, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA.

Angela B G Dos Santos (ABG)

Department of Translational Molecular Pathology, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA.

Francisco Soriano (F)

Clinical Laboratory in Emergency Medicine, Faculdade de Medicina da Universidade de São Paulo, São Paulo, SP, Brazil.

Walcy R Teodoro (WR)

Rheumatology Division, Faculdade de Medicina da Universidade de São Paulo, São Paulo, SP, Brazil.

Pedro Leme Silva (PL)

Laboratory of Pulmonary Investigation, Carlos Chagas Filho Biophysics Institute, Federal University of Rio de Janeiro, Brazil.

Warren Tourtellotte (W)

Department of Pathology, Neurology and Neurosurgery, Cedars-Sinai Medical Center, Los Angeles, CA, USA.

Vera L Capelozzi (VL)

Department of Translational Molecular Pathology, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA.

John Varga (J)

Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.

Natalino H Yoshinari (NH)

Rheumatology Division, Faculdade de Medicina da Universidade de São Paulo, São Paulo, SP, Brazil.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH